NOVABAY PHARMACEUTICALS INC (NBY) Stock Price, Quote, News and Overview
NYSEARCA:NBY - NYSE Arca - US66987P4090 - Common Stock - Currency: USD
NBY Quote, Performance and Key Statistics
0.63
-0.01 (-2.1%)
The current stock price of NBY is 0.63 USD. In the past month the price decreased by -11.28%. In the past year, price decreased by -88.31%.
NBY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About NBY
Company Profile
NovaBay Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Emeryville, California and currently employs 24 full-time employees. The company went IPO on 2007-10-26. NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. The company offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. The company also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
Company Info
NOVABAY PHARMACEUTICALS INC
2000 Powell St Ste 1150
Emeryville CALIFORNIA 94608 US
CEO: Justin Hall
Employees: 25
Company Website: https://novabay.com/
Investor Relations: http://novabay.com/investors/
Phone: 15108998800
NOVABAY PHARMACEUTICALS INC / NBY FAQ
What is the stock price of NOVABAY PHARMACEUTICALS INC today?
The current stock price of NBY is 0.63 USD. The price decreased by -2.1% in the last trading session.
What is the ticker symbol for NOVABAY PHARMACEUTICALS INC stock?
The exchange symbol of NOVABAY PHARMACEUTICALS INC is NBY and it is listed on the NYSE Arca exchange.
On which exchange is NBY stock listed?
NBY stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for NOVABAY PHARMACEUTICALS INC stock?
5 analysts have analysed NBY and the average price target is 0.87 USD. This implies a price increase of 37.62% is expected in the next year compared to the current price of 0.63. Check the NOVABAY PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NOVABAY PHARMACEUTICALS INC worth?
NOVABAY PHARMACEUTICALS INC (NBY) has a market capitalization of 3.08M USD. This makes NBY a Nano Cap stock.
How many employees does NOVABAY PHARMACEUTICALS INC have?
NOVABAY PHARMACEUTICALS INC (NBY) currently has 25 employees.
What are the support and resistance levels for NOVABAY PHARMACEUTICALS INC (NBY) stock?
NOVABAY PHARMACEUTICALS INC (NBY) has a support level at 0.6 and a resistance level at 0.66. Check the full technical report for a detailed analysis of NBY support and resistance levels.
Is NOVABAY PHARMACEUTICALS INC (NBY) expected to grow?
The Revenue of NOVABAY PHARMACEUTICALS INC (NBY) is expected to decline by -25.41% in the next year. Check the estimates tab for more information on the NBY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NOVABAY PHARMACEUTICALS INC (NBY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NBY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NBY, evaluating the profitability, health, valuation and growth aspects
- NOVABAY PHARMACEUTICALS INC (NBY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NOVABAY PHARMACEUTICALS INC (NBY) Sales and EPS estimates to see what analysts future expectations are.
- NOVABAY PHARMACEUTICALS INC (NBY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NOVABAY PHARMACEUTICALS INC (NBY) Insider and Institutional Ownership to learn about the owners and their transactions.
- NOVABAY PHARMACEUTICALS INC (NBY) Stock Chart to make your own analysis
- NOVABAY PHARMACEUTICALS INC (NBY) Latest news and press-releases to stay up to date.
Does NOVABAY PHARMACEUTICALS INC (NBY) stock pay dividends?
NBY does not pay a dividend.
When does NOVABAY PHARMACEUTICALS INC (NBY) report earnings?
NOVABAY PHARMACEUTICALS INC (NBY) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of NOVABAY PHARMACEUTICALS INC (NBY)?
NOVABAY PHARMACEUTICALS INC (NBY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-53.5).
What is the Short Interest ratio of NOVABAY PHARMACEUTICALS INC (NBY) stock?
The outstanding short interest for NOVABAY PHARMACEUTICALS INC (NBY) is 1.67% of its float. Check the ownership tab for more information on the NBY short interest.
NBY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBY. When comparing the yearly performance of all stocks, NBY is a bad performer in the overall market: 95.61% of all stocks are doing better.
NBY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NBY. Both the profitability and financial health of NBY have multiple concerns.
NBY Financial Highlights
Over the last trailing twelve months NBY reported a non-GAAP Earnings per Share(EPS) of -53.5. The EPS increased by 42.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -427.26% | ||
| ROE | -1545.24% | ||
| Debt/Equity | 0.05 |
NBY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to NBY. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 98.72% and a revenue growth -25.41% for NBY